Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian epithelial or primary peritoneal cavity cancer.
研究概览
详细说明
OBJECTIVES:
- Determine the antitumor activity of capecitabine in patients with recurrent, platinum-sensitive ovarian epithelial or primary peritoneal cavity cancer.
- Determine the nature and degree of toxicity of this drug in this patient population.
OUTLINE: This is a multicenter study.
Patients receive oral capecitabine twice daily for 14 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study within 6-12 months.
研究类型
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 4N2
- Tom Baker Cancer Center - Calgary
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
California
-
Los Angeles、California、美国、90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Angeles、California、美国、90033-0804
- USC/Norris Comprehensive Cancer Center and Hospital
-
Orange、California、美国、92868
- Chao Family Comprehensive Cancer Center
-
-
Colorado
-
Denver、Colorado、美国、80010
- University of Colorado Cancer Center
-
-
Florida
-
Tampa、Florida、美国、33612-9497
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Illinois
-
Chicago、Illinois、美国、60612
- Rush-Presbyterian-St. Luke's Medical Center
-
-
Indiana
-
Indianapolis、Indiana、美国、46202-5289
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City、Iowa、美国、52242-1009
- Holden Comprehensive Cancer Center at the University of Iowa
-
-
Maryland
-
Bethesda、Maryland、美国、20892
- Radiation Oncology Branch
-
-
Massachusetts
-
Boston、Massachusetts、美国、02111
- Tufts University School of Medicine
-
Worcester、Massachusetts、美国、01655
- University of Massachusetts Memorial Medical Center
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- University of Minnesota Cancer Center
-
Rochester、Minnesota、美国、55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Columbia、Missouri、美国、65203
- Ellis Fischel Cancer Center - Columbia
-
Saint Louis、Missouri、美国、63110
- Washington University School of Medicine
-
-
New Jersey
-
Camden、New Jersey、美国、08103
- Cooper Hospital/University Medical Center
-
-
New York
-
Brooklyn、New York、美国、11203
- State University of New York Health Science Center at Brooklyn
-
New York、New York、美国、10021
- Memorial Sloan-Kettering Cancer Center
-
Stony Brook、New York、美国、11790-7775
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham、North Carolina、美国、27710
- Duke Comprehensive Cancer Center
-
Winston-Salem、North Carolina、美国、27157-1082
- Comprehensive Cancer Center at Wake Forest University
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic Taussig Cancer Center
-
Columbus、Ohio、美国、43210-1240
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73190
- University of Oklahoma College of Medicine
-
-
Pennsylvania
-
Abington、Pennsylvania、美国、19001
- Abington Memorial Hospital
-
Hershey、Pennsylvania、美国、17033
- Milton S. Hershey Medical Center
-
Philadelphia、Pennsylvania、美国、19107-5541
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
-
-
Texas
-
Houston、Texas、美国、77030-4009
- University of Texas - MD Anderson Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
- Histologically proven recurrent ovarian epithelial or primary peritoneal cavity cancer
Measurable disease
- At least 1 unidimensionally measurable lesion
- Ascites and pleural effusions are not considered measurable disease
Prior therapy must include 1 platinum-based chemotherapy regimen for primary disease containing carboplatin, cisplatin, or another organoplatinum compound
- Treatment-free interval of 6-12 months after response to platinum therapy
- Not eligible for higher priority GOG protocol
PATIENT CHARACTERISTICS:
Age:
- Any age
Performance status:
- GOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least lower limit of normal
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
Renal:
- Creatinine clearance at least 50 mL/min
Other:
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No neuropathy (sensory and motor) greater than grade 1
- No other malignancy within the past 5 years except nonmelanoma skin cancer
- No concurrent active infection requiring antibiotics
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 3 weeks since prior biologic or immunologic therapy
- No concurrent prophylactic filgrastim (G-CSF)
Chemotherapy:
- See Disease Characteristics
- If no prior therapy with paclitaxel, a second regimen including paclitaxel allowed
- No prior capecitabine or fluorouracil
- No prior chemotherapy for recurrent or persistent disease, including pretreatment with initial chemotherapy regimens
- Recovered from prior chemotherapy
Endocrine therapy:
- At least 1 week since prior hormonal therapy directed at malignant tumor
- Concurrent continuation of hormone replacement therapy allowed
Radiotherapy:
- At least 3 weeks since prior radiotherapy and recovered
- No prior radiotherapy to site(s) of measurable disease
- No prior radiotherapy to more than 25% of bone marrow
Surgery:
- Recovered from prior surgery
Other:
- No prior cancer treatment that would preclude study therapy
- No concurrent amifostine or other protective reagents
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
合作者和调查者
调查人员
- 学习椅:Agustin Garcia, MD、University of Southern California
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
卡培他滨的临床试验
-
AstraZenecaSWOG Clinical Trials Partnerships; Daiichi Sankyo招聘中乳腺癌美国, 中国, 丹麦, 英国, 大韩民国, 加拿大, 德国, 意大利, 比利时, 西班牙, 日本, 法国, 台湾, 希腊, 巴西, 瑞典, 波多黎各
-
AstraZenecaDaiichi Sankyo招聘中乳腺癌西班牙, 中国, 美国, 意大利, 英国, 大韩民国, 比利时, 法国, 德国, 日本, 越南, 加拿大, 巴西, 印度, 马来西亚, 台湾, 澳大利亚, 奥地利, 泰国, 火鸡, 香港, 波兰, 瑞士, 保加利亚, 匈牙利, 新加坡